Diagnosis and Risk Stratification of Dilated Cardiomyopathy: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
André Ferreira
,
Vera Ferreira
,
Miguel Marques Antunes
,
Ana Lousinha
,
Tiago Pereira-da-Silva
,
Diana Antunes
,
Pedro Silva Cunha
,
Mário Oliveira
,
Rui Cruz Ferreira
,
Sílvia Aguiar Rosa

Dilated cardiomyopathy (DCM) represents one of the most common causes of non-ischemic heart failure, characterised by ventricular dilation alongside systolic dysfunction. Despite advances in therapy, DCM mortality rates remain high, and it is one of the leading causes of heart transplantation. Developments in complementary diagnostic procedures, namely cardiac magnetic resonance and genetic testing, have shed new light on DCM understanding and management. 

  • dilated cardiomyopathy
  • risk stratification
  • cardiovascular magnetic resonance

1. Introduction

Dilated cardiomyopathy (DCM), also sometimes referred to as dilated non-ischaemic cardiomyopathy, encompasses a group of aetiologically heterogeneous myocardial disorders defined by left ventricular (LV) or biventricular dilation alongside systolic dysfunction, defined by abnormal left ventricle ejection fraction (LVEF), not otherwise explained by abnormal loading conditions such as hypertension, valvular, or coronary artery disorders [1]. DCM is common, with an estimated prevalence of up to 1 in 250 of the population [2]. Despite the remarkable progress in heart failure (HF) therapies over recent decades, DCM mortality rates remain high, and it is one of the leading causes of heart transplantation [3]. Causes of death include HF progression (pump failure) or sudden cardiac death (SCD) [4]. Recent research has shown that many patients present minor structural cardiac abnormalities and arrhythmogenic phenotypes before overt heart failure symptoms [5]. This has raised several diagnostic and management challenges, including the differential diagnosis with other phenotypically similar conditions, the identification of patients at increased risk of malignant arrhythmias such as high-grade atrioventricular block, ventricular tachycardia or fibrillation and those who will have a worse response to medical therapy, with a lower reverse-remodelling rate. Accurately diagnosing dilated cardiomyopathy and stratifying patients based on arrhythmic risk is critical for guiding clinical decision-making and improving outcomes.

2. Diagnostic Workup

Considering the broad spectrum of disorders that cause DCM, a systematic approach helps to identify and manage this condition, especially the more uncommon but clinically significant forms of DCM. A dedicated diagnostic workup (Figure 1) will lead to an aetiology-oriented approach to help with risk stratification and advice on therapeutic interventions.
/media/item_content/202305/646725d27cbf2biomedicines-11-00834-g001.png
Figure 1. Integrated approach for the diagnostic work-up and risk stratification of DCM. Abbreviations; LVEF: left ventricular ejection fraction, CV: cardiovascular, ECG: electrocardiography, ACM: arrhythmogenic cardiomyopathy, DCM: dilated cardiomyopathy, NSVT: non-sustained ventricular tachycardia, PVC: premature ventricular contraction, RV: right ventricle, GLS: global longitudinal strain, LGE: late gadolinium enhancement, ECV: extracellular volume, TTN: Titin, LMNA: Lamin A/C, MYH7: Myosin heavy chain, TNT2: Troponin T, MYBPC3: Myosin binding protein C, PLN: Phospholamban, FLNC: Filamin C, RBM 20: RNA Binding Motif Protein-20.
The clinical workup starts with family and personal history and a physical examination which considers the patient’s age [6]. The pedigree evaluation should include a three-generation family tree focusing on premature cardiovascular events (e.g., sudden death, HF) and associated cardiac (e.g., arrhythmias, conduction disease, pacemaker/implantable cardioverter defibrillator) and noncardiac (e.g., skeletal myopathy, renal failure, auditory/visual defects) phenotypes [7]. In addition, cardiac and extracardiac personal history should be recorded, especially when a syndromic or metabolic cause of cardiomyopathy is suspected [7].
Initial laboratory testing should always include a complete blood count, renal function, liver function tests, urine analysis for proteinuria, creatine kinase (CK), serum iron, ferritin, calcium, phosphate, natriuretic peptides, and thyroid-stimulating hormone [6]. In addition, an electrocardiogram (ECG) should be included in the initial workup. It may be completely normal in the early stages of DCM. However, it may present signs of left ventricular hypertrophy, nonspecific-ST-segment and T-wave changes, left bundle branch block (LBBB), or nonspecific intraventricular conduction delay. In more advanced stages of DCM, it can exhibit low voltage with low R-wave amplitudes, which indicates widespread myocardial fibrosis [8].
Imaging is crucial for diagnosing DCM, risk stratification, management, and treatment monitoring. Echocardiography should be the first imaging method performed, as it provides information on chamber dimensions and morphology, systolic and diastolic function, the severity of valve disease, and non-invasive hemodynamic assessment in a broadly available, non-invasive, and cost-effective manner [5]. Cardiac magnetic resonance (CMR) is the gold standard technique for quantifying volumes and LVEF, with better accuracy and reproducibility than echocardiography [5][9]. CMR also adds value in determining specific aetiologies such as sarcoid and myocarditis through tissue characterisation evaluation (T1- and T2-weighted sequences or mapping and late gadolinium enhancement) and directs further investigations and cause-specific treatment [9].
Identifying clinical features suggestive of specific diseases should lead to a second-level diagnostic workup that may include more specific biochemical analyses, endomyocardial biopsy, and genetic testing.

3. Differential Diagnosis

In the differential diagnosis of DCM, it is mandatory to exclude the most frequent causes of LV dysfunction, such as coronary artery disease and valvular disease, where LV dilatation can occur due to adverse remodelling. The exclusion of epicardial coronary artery stenosis is carried out using invasive coronary angiography, the gold standard, or by computerised tomography in patients not at high risk of atherosclerosis. Valvular disease should be systematically sought through various imaging methods [6].
Other less-common cardiomyopathies can have phenotypic similarities with DCM. They must also be considered in the differential diagnosis, such as left ventricular non-compaction cardiomyopathy (LVNC) and peripartum cardiomyopathy (PPCM).
LVNC is an unclassified cardiomyopathy that, in advanced cases, can present findings similar to DCM (dilated and impaired LV function) [10]. Echocardiographic findings compatible with LVNC consist of prominent trabeculations, and deep recesses found mainly in the LV’s apex and free wall and a two-layer wall structure, with an end-systolic ratio of >2 between the non-compact subendocardial layer and the compact subepicardial layer [10][11]. In addition, imaging with cardiac magnetic resonance (CMR) may show the extent of myocardial involvement and the degree of fibrosis with late gadolinium enhancement (LGE) [11].
PPCM is an idiopathic cardiomyopathy with HF, secondary to LV systolic dysfunction, usually seen in the last months of pregnancy or the first five months after delivery. A reduction in LVEF is required to establish the diagnosis, but the left ventricle may or may not be dilated [12][13].
Despite the distinct classification, DCM and LV hyper trabeculation often overlap due to LV remodelling, and DCM and PPCM may share the same genetic background [13].
Findings of extracardiac manifestations, namely neuromuscular involvement, should alert for other rarer syndromic or metabolic cardiomyopathies [14].

Differential Diagnosis of Dilated and Arrhythmogenic Cardiomyopathy

Arrhythmogenic cardiomyopathy (ACM) is a genetic heart muscle disease characterised by the replacement of the ventricular myocardium with fibrofatty tissue. Although initially defined as a condition that distinctively affected the right ventricle (RV), more recent post mortem and contrast-enhanced CMR investigations revealed that the left ventricle is often involved [15][16]. ACM is distinguished from DCM by a propensity towards arrhythmia exceeding the degree of ventricular dysfunction. However, there is a subgroup of DCM patients with clinical presentations of arrhythmia and syncope early in the disease course [15][16][17]. The term ‘arrhythmogenic DCM’ has been used to describe these patients. This subset of arrhythmogenic DCM patients shows genotypic and phenotypic features that overlap with those of arrhythmogenic left ventricle cardiomyopathy (ALVC): more frequent arrhythmic events, LV systolic dysfunction, mild LV dilatation, and myocardial fibrosis. Consequently, the differential diagnosis between DCM and ALVC may be challenging, but it is essential, due to their different management and prognosis [16][17][18].
Conduction system disease and frequent atrial or ventricular arrhythmias (VA), especially with a near-normal LVEF, should raise suspicion of ACM [16]. Low voltages at limb leads, inverted T waves in V4-V6, frequent premature ventricular contractions (PVC), and non-sustained ventricular tachycardia (NSVT) of right bundle branch block morphology are findings suggestive of ALVC [16][17][19]. Therefore, a 24-h Holter monitoring should be performed on every patient suspected of ACM. The presence of >1000 PVC or NSVT should raise concerns about the propensity for arrhythmogenicity [16].
While the typical phenotype of DCM consists of LV dilatation with systolic dysfunction, the ALVC remodelling pattern may present with a normal or only slightly depressed LV function [16][20]. In distinguishing both entities, an imaging study using CMR is fundamental. While LGE is detected in less than half of DCM cases, nearly all patients with ALVC with LV systolic dysfunction show the presence of LV LGE [21][22]. The distribution of LGE differs between the two conditions: in ALVC, it is predominantly distributed in the subepicardial inferolateral regions; in DCM, it usually affects mid-mural septal segments [21]. Fatty myocardial infiltration may be assessed in dedicated sequences in the CMR study, and is often observed in the same regions of LGE. LV myocardial fibrosis/LGE is significantly higher in patients with ALVC than those with DCM [22][23]. It is known that while the LGE in DCM represents an epiphenomenon and is unrelated to the reduction of the LV systolic function, in ALVC, it is directly correlated with the degree of LV dysfunction [22][23][24].
In more advanced stages of ALVC, fibrofatty tissue can deposit in multiple segments of the LV free wall and septum, with transmural involvement, leading to severe systolic dysfunction [20]. Demonstrating an ACM-causing gene mutation associated with a consistent phenotype is mandatory for diagnosing ALVC [16]. The predominant genetic background in ALVC includes the mutations of genes encoding for desmosomal proteins, lamin A/C, phospholamban, filamin C, RMB20, and SCN5A. In DCM, the most frequent genes involved encode cytoskeleton, muscular sarcomere, and nuclear envelope proteins. Nonetheless, significant genetic overlap exists [17][23][25].

4. Aetiologies

DCM is a heterogeneous disease encompassing various underlying causes, including genetic and acquired disorders. A positive family history can be detected in up to 30–50% of DCM cases, and a causative genetic mutation can be identified in up to 40% of DCM cases [2][6][26]. In the presence of positive cases in the family, sarcomeric, neuromuscular, and mitochondrial disorders are the most frequent aetiologies. External factors such as exposure to toxins, diabetes, arrhythmia, myocarditis, and pregnancy often contribute to the development of the phenotype and outcome [26]. The non-genetic causes of DCM include infectious (viral or non-viral), autoimmune, toxic, infiltrative-related causes, nutritional deficiencies, and endocrine disorders [26]. 

5. Risk Stratification and Prognosis

Despite advances in DCM treatments, 10-year survival remains less than 60%, with death preceded by numerous HF exacerbations. Remarkably, the clinical course of DCM patients varies widely, ranging from rapidly progressive HF or SCD to LVRR, denoting high complexity in assessing the individual risk [2][4][5]. Various elements from clinical presentation, previous medical history and comorbidities, physical examination, and laboratory and imaging investigations are available, to enhance risk stratification.

5.1. Electrocardiogram

A fragmented QRS, longer QRS duration, antero-lateral T-wave inversion and low QRS voltage in the ECG are associated with a higher risk of major arrhythmic outcomes, including death due to arrhythmia, appropriate implantable cardioverter-defibrillator (ICD) therapy, documented VT/VF, and all-cause mortality [27]. Previous studies showed that longer QRS (>120 ms), together with LGE on CMR, provided incremental value to LGE alone in predicting all-cause mortality [28].
The 24-h Holter monitoring demonstrates NSVT in 40–60% of patients and polymorphic PVC in up to 90% of DCM patients. The presence of NSVT and frequent PVC (≥1000 PVC or ≥50 couplets/24 h) increases the arrhythmic risk, mainly when combined with a family history of malignant VA or SCD [29][30].

5.2. Echocardiography

Imaging with echocardiography is not only indispensable in diagnosing DCM, but it also provides multiple prognostic indicators. LV systolic function is one of the most critical evaluations. It has been considered the primary determinant of prognosis, guiding patient management and subsequent treatment, including the indication for ICD, cardiac resynchronisation therapy (CRT), or the discontinuation of cardiotoxic chemotherapy. For a more accurate LV function assessment, it is recommended that a 3-dimensional (3D) echocardiography should be performed to determine LVEF, when available in experienced laboratories, as it can overcome some of the limitations inherent to a 2-dimensional (2D) LVEF measurement [31].

5.3. Cardiac Magnetic Resonance

5.3.1. Late Gadolinium Enhancement

Myocardial fibrosis occurs due to collagen accumulation resulting in interstitial expansion without myocardial necrosis (interstitial fibrosis) and from cardiomyocyte death (replacement fibrosis). There is a good histological correlation between LGE and replacement fibrosis, but LGE has a low sensitivity for interstitial fibrosis [32].
Late gadolinium enhancement is present in around 30% of patients with DCM, typically in a mid-wall pattern. It has been associated with the occurrence of major VA consistently across all subgroups, regardless of LVEF. Besides the association with a four-fold increased risk of SCD or aborted SCD, LGE is an independent predictor of cardiovascular mortality and HF hospitalisation. Prognostic value is added with LGE beyond LVEF, NHYA class, and common baseline cardiovascular covariates [32][33][34].

5.3.2. T1 and Extracellular Volume

The study of interstitial fibrosis using T1 mapping and extracellular volume (ECV) estimation is an expanding area of CMR.
Techniques for calculating T1 mapping have shown a good correlation with histologically graded myocardial fibrosis and, as such, may allow for a more sensitive detection of the early disease process, and initiation of respective treatment before overt pathology [35]. In addition, a higher native-T1 value of myocardium constitutes an independent predictor of all-cause mortality and HF events in patients with DCM [36], and is also a predictor of arrhythmic outcomes, including the appropriate ICD therapy or sustained VA [37].
Extracellular volume has been shown to hold prognostic value incremental to LGE or native-T1 mapping [38]. A strong association has been demonstrated between ECV and major adverse cardiac events, including heart failure hospitalisations and all-cause mortality [37][38]. Abnormal ECV measurements yield a 2.8-fold increased odds of negative outcomes, independently of age, sex, functional class, and LVEF [38]. Patients with DCM and a high ECV and prolonged QRS duration had a significantly worse prognosis than those with normal ECV and QRS duration [37][38].

5.3.3. Feature-Tracking Strain Analysis

Feature-tracking (FT) strain analysis is a promising tool for improving DCM patients’ risk stratification. Evidence suggests that survival prediction and risk stratification in DCM may be strengthened by FT parameters, independently of clinical parameters, biomarkers, LVEF, and LGE. For example, a preserved GLS determined by CMR carried a good prognosis, even in patients with LVEF < 35% and those with LGE [39].

5.4. Genetic Testing

DCM has a recognisable genetic background that significantly overlaps with other cardiomyopathies, which could partially explain its wide heterogeneity. Current evidence suggests that 30% to 40% of DCM cases are caused by pathogenic or likely-pathogenic gene variants that occur in more than 40 genes associated with the condition [14][40][41]. Genetic testing can influence clinical management in patients with DCM, as once a mutation is identified and its pathogenic role and mode of inheritance are established, that information can be used for guidance of therapy and family screening.
Figure 2 demonstrates the remarkably different phenotype and diagnostic findings that can be found in patients with different genetic mutations.
/media/item_content/202305/646725f64ff4ebiomedicines-11-00834-g002.png
Figure 2. (I) Case 1 of a patient with a heterozygous variant c.1150G>T, p.(Glu384*) in the LMNA gene [NM_170707.3], classified as pathogenic, exhibiting atrial fibrillation, low QRS voltage, QS morphology in leads V1V3 and two polymorphic ventricular complexes on ECG (A); Echocardiography showing dilated left ventricle (LV) and severely reduced left ventricular ejection fraction (LVEF) (33%) and impaired global longitudinal strain (GLS), average GLS −10.8% (C,E) and cardiovascular magnetic resonance revealing a pattern of laminar intramural late gadolinium enhancement (LGE) in the septum and inferior wall (G). (II) Case 2 of a patient with a heterozygous variant c.54278_54279delCT (p.Pro18093Argfs*5) in the TTN gene [NM_001256850.1], classified as likely pathogenic, showing diffuse ST-T change on ECG (B); Echocardiography presented dilated LV, global hypokinesis and severely impaired LV systolic function (LVEF 12%, GLS -2.8%) (D,F) and no areas of LGE found on CMR (H).

6. Prediction of Left Ventricle Reverse Remodelling

DCM is a dynamic disease, with up to 40% of patients experiencing LVRR, defined as an improvement in LVEF and reduction in ventricular volumes on OMT [29]. Patients who demonstrate this phenomenon have a better prognosis than those who do not, with a transplant-free survival of 95% versus 71%, respectively, at a 180-month follow-up [42].
Early diagnosis and treatment intervention is key in promoting LVRR in DCM patients, given recent findings underscoring the rapid and irreversible changes denoted in patients with a prolonged symptomatic-disease course [43][44].
Recent studies identified hypertension, absence of a family history of DCM, symptom duration <90 days, LVEF < 35%, and QRS duration < 116 ms, as independent clinical predictors of LVRR in patients with DCM [44].
LBBB and longer QRS duration at baseline suggest a low probability of future LVRR [45]. Furthermore, a wide QRS duration was reported to be associated with diffuse myocardial fibrosis on CMR [46].
The extent of LGE is a robust independent predictor of LVRR, with a lower extent of LGE predicting a higher LVRR rate, regardless of the severity of LV dysfunction or dilation [28][47]. In addition, myocardial oedema in T2 imaging and increased ECV fraction have been inversely correlated with LVRR [48][49].
Regarding genetic testing, TTN variants are independently associated with LVRR, despite a lower baseline LVEF [50]. Compared to TTN, patients with LMNA variants showed high baseline LVEF with less frequent LVRR. Rare variants of the structural cytoskeleton Z-disk gene are independently associated with a lower rate of LVRR [50][51].

This entry is adapted from the peer-reviewed paper 10.3390/biomedicines11030834

References

  1. Pinto, Y.M.; Elliott, P.M.; Arbustini, E.; Adler, Y.; Anastasakis, A.; Böhm, M.; Duboc, D.; Gimeno, J.; de Groote, P.; Imazio, M.; et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: A position statement of the ESC working group on myocardial and pericardial diseases. Eur. Heart J. 2016, 37, 1850–1858.
  2. Hershberger, R.E.; Hedges, D.J.; Morales, A. Dilated cardiomyopathy: The complexity of a diverse genetic architecture. Nat. Rev. Cardiol. 2013, 10, 531–547.
  3. Lund, L.H.; Edwards, L.B.; Dipchand, A.I.; Goldfarb, S.; Kucheryavaya, A.Y.; Levvey, B.J.; Meiser, B.; Rossano, J.W.; Yusen, R.D.; Stehlik, J. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. J. Heart Lung Transplant. 2016, 35, 1158–1169.
  4. Halliday, B.P.; Gulati, A.; Ali, A.; Newsome, S.; Lota, A.; Tayal, U.; Vassiliou, V.S.; Arzanauskaite, M.; Izgi, C.; Krishnathasan, K.; et al. Sex- and age-based differences in the natural history and outcome of dilated cardiomyopathy. Eur. J. Heart Fail. 2018, 20, 1392–1400.
  5. Donal, E.; Delgado, V.; Bucciarelli-Ducci, C.; Galli, E.; Haugaa, K.H.; Charron, P.; Voigt, J.U.; Cardim, N.; Masci, P.G.; Galderisi, M.; et al. Multimodality imaging in the diagnosis, risk stratification, and management of patients with dilated cardiomyopathies: An expert consensus document from the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging 2019, 20, 1075–1093.
  6. Japp, A.G.; Gulati, A.; Cook, S.A.; Cowie, M.R.; Prasad, S.K. The Diagnosis and Evaluation of Dilated Cardiomyopathy. J. Am. Coll. Cardiol. 2016, 67, 2996–3010.
  7. Rapezzi, C.; Arbustini, E.; Caforio, A.L.P.; Charron, P.; Gimeno-Blanes, J.; Heliö, T.; Linhart, A.; Mogensen, J.; Pinto, Y.; Ristic, A.; et al. Diagnostic work-up in cardiomyopathies: Bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 2012, 34, 1448–1458.
  8. Grimm, W.; Christ, M.; Bach, J.; Müller, H.H.; Maisch, B. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: Results of the Marburg Cardiomyopathy Study. Circulation 2003, 108, 2883–2891.
  9. Patel, A.R.; Kramer, C.M. Role of Cardiac Magnetic Resonance in the Diagnosis and Prognosis of Nonischemic Cardiomyopathy. JACC Cardiovasc. Imaging 2017, 10, 1180–1193.
  10. Guigui, S.A.; Horvath, S.A.; Arenas, I.A.; Mihos, C.G. Cardiac geometry, function and mechanics in left ventricular non-compaction cardiomyopathy with preserved ejection fraction. J. Echocardiogr. 2022, 20, 144–150.
  11. Srivastava, S.; Yavari, M.; Al-Abcha, A.; Banga, S.; Abela, G. Ventricular non-compaction review. Heart Fail. Rev. 2022, 27, 1063–1076.
  12. Regitz-Zagrosek, V.; Roos-Hesselink, J.W.; Bauersachs, J.; Blomström-Lundqvist, C.; Cífková, R.; De Bonis, M.; Iung, B.; Johnson, M.R.; Kintscher, U.; Kranke, P.; et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur. Heart J. 2018, 39, 3165–3241.
  13. Davis, M.B.; Arany, Z.; McNamara, D.M.; Goland, S.; Elkayam, U. Peripartum Cardiomyopathy: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2020, 75, 207–221.
  14. Hershberger, R.E.; Givertz, M.M.; Ho, C.Y.; Judge, D.P.; Kantor, P.F.; McBride, K.L.; Morales, A.; Taylor, M.R.G.; Vatta, M.; Ware, S.M. Genetic evaluation of cardiomyopathy: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 2018, 20, 899–909.
  15. Miles, C.; Finocchiaro, G.; Papadakis, M.; Gray, B.; Westaby, J.; Ensam, B.; Basu, J.; Parry-Williams, G.; Papatheodorou, E.; Paterson, C.; et al. Sudden Death and Left Ventricular Involvement in Arrhythmogenic Cardiomyopathy. Circulation 2019, 139, 1786–1797.
  16. Corrado, D.; Perazzolo Marra, M.; Zorzi, A.; Beffagna, G.; Cipriani, A.; Lazzari, M.; Migliore, F.; Pilichou, K.; Rampazzo, A.; Rigato, I.; et al. Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria. Int. J. Cardiol. 2020, 319, 106–114.
  17. Spezzacatene, A.; Sinagra, G.; Merlo, M.; Barbati, G.; Graw, S.L.; Brun, F.; Slavov, D.; Di Lenarda, A.; Salcedo, E.E.; Towbin, J.A.; et al. Arrhythmogenic Phenotype in Dilated Cardiomyopathy: Natural History and Predictors of Life-Threatening Arrhythmias. J. Am. Heart Assoc. 2015, 4, e002149.
  18. Corrado, D.; van Tintelen, P.J.; McKenna, W.J.; Hauer, R.N.W.; Anastastakis, A.; Asimaki, A.; Basso, C.; Bauce, B.; Brunckhorst, C.; Bucciarelli-Ducci, C.; et al. Arrhythmogenic right ventricular cardiomyopathy: Evaluation of the current diagnostic criteria and differential diagnosis. Eur. Heart J. 2020, 41, 1414–1429.
  19. Towbin, J.A.; McKenna, W.J.; Abrams, D.J.; Ackerman, M.J.; Calkins, H.; Darrieux, F.C.C.; Daubert, J.P.; de Chillou, C.; DePasquale, E.C.; Desai, M.Y.; et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019, 16, e301–e372.
  20. Hoorntje, E.T.; Te Rijdt, W.P.; James, C.A.; Pilichou, K.; Basso, C.; Judge, D.P.; Bezzina, C.R.; van Tintelen, J.P. Arrhythmogenic cardiomyopathy: Pathology, genetics, and concepts in pathogenesis. Cardiovasc. Res. 2017, 113, 1521–1531.
  21. Chun, K.H.; Oh, J.; Hong, Y.J.; Yu, H.T.; Lee, C.J.; Kim, T.H.; Joung, B.; Pak, H.N.; Lee, M.H.; Kim, Y.J.; et al. Prognostic Cardiac Magnetic Resonance Markers of Left Ventricular Involvement in Arrhythmogenic Cardiomyopathy for Predicting Heart Failure Outcomes. J. Am. Heart Assoc. 2022, 11, e023167.
  22. Cipriani, A.; Bauce, B.; De Lazzari, M.; Rigato, I.; Bariani, R.; Meneghin, S.; Pilichou, K.; Motta, R.; Aliberti, C.; Thiene, G.; et al. Arrhythmogenic Right Ventricular Cardiomyopathy: Characterization of Left Ventricular Phenotype and Differential Diagnosis With Dilated Cardiomyopathy. J. Am. Heart Assoc. 2020, 9, e014628.
  23. Segura-Rodríguez, D.; Bermúdez-Jiménez, F.J.; Carriel, V.; López-Fernández, S.; González-Molina, M.; Oyonarte Ramírez, J.M.; Fernández-Navarro, L.; García-Roa, M.D.; Cabrerizo, E.M.; Durand-Herrera, D.; et al. Myocardial fibrosis in arrhythmogenic cardiomyopathy: A genotype-phenotype correlation study. Eur. Heart J. Cardiovasc. Imaging 2020, 21, 378–386.
  24. Cipriani, A.; Mattesi, G.; Bariani, R.; Cecere, A.; Martini, N.; De Michieli, L.; Da Pozzo, S.; Corradin, S.; De Conti, G.; Zorzi, A.; et al. Cardiac magnetic resonance imaging of arrhythmogenic cardiomyopathy: Evolving diagnostic perspectives. Eur. Radiol. 2023, 33, 270–282.
  25. Groeneweg, J.A.; van der Zwaag, P.A.; Olde Nordkamp, L.R.; Bikker, H.; Jongbloed, J.D.; Jongbloed, R.; Wiesfeld, A.C.; Cox, M.G.; van der Heijden, J.F.; Atsma, D.E.; et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy according to revised 2010 task force criteria with inclusion of non-desmosomal phospholamban mutation carriers. Am. J. Cardiol. 2013, 112, 1197–1206.
  26. Bondue, A.; Arbustini, E.; Bianco, A.; Ciccarelli, M.; Dawson, D.; De Rosa, M.; Hamdani, N.; Hilfiker-Kleiner, D.; Meder, B.; Leite-Moreira, A.F.; et al. Complex roads from genotype to phenotype in dilated cardiomyopathy: Scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovasc. Res. 2018, 114, 1287–1303.
  27. Goldberger, J.J.; Subačius, H.; Patel, T.; Cunnane, R.; Kadish, A.H. Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. J. Am. Coll. Cardiol. 2014, 63, 1879–1889.
  28. Marume, K.; Noguchi, T.; Tateishi, E.; Morita, Y.; Kamakura, T.; Ishibashi, K.; Noda, T.; Miura, H.; Nishimura, K.; Nakai, M.; et al. Mortality and Sudden Cardiac Death Risk Stratification Using the Noninvasive Combination of Wide QRS Duration and Late Gadolinium Enhancement in Idiopathic Dilated Cardiomyopathy. Circ. Arrhythmia Electrophysiol. 2018, 11, e006233.
  29. Merlo, M.; Cannatà, A.; Gobbo, M.; Stolfo, D.; Elliott, P.M.; Sinagra, G. Evolving concepts in dilated cardiomyopathy. Eur. J. Heart Fail. 2018, 20, 228–239.
  30. Daubert, J.P.; Zareba, W.; Hall, W.J.; Schuger, C.; Corsello, A.; Leon, A.R.; Andrews, M.L.; McNitt, S.; Huang, D.T.; Moss, A.J. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. J. Am. Coll. Cardiol. 2006, 47, 98–107.
  31. Jenkins, C.; Bricknell, K.; Hanekom, L.; Marwick, T.H. Reproducibility and accuracy of echocardiographic measurements of left ventricular parameters using real-time three-dimensional echocardiography. J. Am. Coll. Cardiol. 2004, 44, 878–886.
  32. Becker, M.A.J.; Cornel, J.H.; van de Ven, P.M.; van Rossum, A.C.; Allaart, C.P.; Germans, T. The Prognostic Value of Late Gadolinium-Enhanced Cardiac Magnetic Resonance Imaging in Nonischemic Dilated Cardiomyopathy: A Review and Meta-Analysis. JACC Cardiovasc. Imaging 2018, 11, 1274–1284.
  33. Di Marco, A.; Anguera, I.; Schmitt, M.; Klem, I.; Neilan, T.G.; White, J.A.; Sramko, M.; Masci, P.G.; Barison, A.; McKenna, P.; et al. Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated Cardiomyopathy: Systematic Review and Meta-Analysis. JACC Heart Fail. 2017, 5, 28–38.
  34. Halliday, B.P.; Baksi, A.J.; Gulati, A.; Ali, A.; Newsome, S.; Izgi, C.; Arzanauskaite, M.; Lota, A.; Tayal, U.; Vassiliou, V.S.; et al. Outcome in Dilated Cardiomyopathy Related to the Extent, Location, and Pattern of Late Gadolinium Enhancement. JACC Cardiovasc. Imaging 2019, 12, 1645–1655.
  35. aus dem Siepen, F.; Buss, S.J.; Messroghli, D.; Andre, F.; Lossnitzer, D.; Seitz, S.; Keller, M.; Schnabel, P.A.; Giannitsis, E.; Korosoglou, G.; et al. T1 mapping in dilated cardiomyopathy with cardiac magnetic resonance: Quantification of diffuse myocardial fibrosis and comparison with endomyocardial biopsy. Eur. Heart J. Cardiovasc. Imaging 2015, 16, 210–216.
  36. Puntmann, V.O.; Carr-White, G.; Jabbour, A.; Yu, C.Y.; Gebker, R.; Kelle, S.; Hinojar, R.; Doltra, A.; Varma, N.; Child, N.; et al. T1-Mapping and Outcome in Nonischemic Cardiomyopathy: All-Cause Mortality and Heart Failure. JACC Cardiovasc. Imaging 2016, 9, 40–50.
  37. Chen, Z.; Sohal, M.; Voigt, T.; Sammut, E.; Tobon-Gomez, C.; Child, N.; Jackson, T.; Shetty, A.; Bostock, J.; Cooklin, M.; et al. Myocardial tissue characterization by cardiac magnetic resonance imaging using T1 mapping predicts ventricular arrhythmia in ischemic and non-ischemic cardiomyopathy patients with implantable cardioverter-defibrillators. Heart Rhythm 2015, 12, 792–801.
  38. Vita, T.; Gräni, C.; Abbasi, S.A.; Neilan, T.G.; Rowin, E.; Kaneko, K.; Coelho-Filho, O.; Watanabe, E.; Mongeon, F.P.; Farhad, H.; et al. Comparing CMR Mapping Methods and Myocardial Patterns Toward Heart Failure Outcomes in Nonischemic Dilated Cardiomyopathy. JACC Cardiovasc. Imaging 2019, 12, 1659–1669.
  39. Romano, S.; Judd, R.M.; Kim, R.J.; Kim, H.W.; Klem, I.; Heitner, J.F.; Shah, D.J.; Jue, J.; White, B.E.; Indorkar, R.; et al. Feature-Tracking Global Longitudinal Strain Predicts Death in a Multicenter Population of Patients With Ischemic and Nonischemic Dilated Cardiomyopathy Incremental to Ejection Fraction and Late Gadolinium Enhancement. JACC Cardiovasc. Imaging 2018, 11, 1419–1429.
  40. Fatkin, D.; Huttner, I.G.; Kovacic, J.C.; Seidman, J.G.; Seidman, C.E. Precision Medicine in the Management of Dilated Cardiomyopathy: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2019, 74, 2921–2938.
  41. Haas, J.; Frese, K.S.; Peil, B.; Kloos, W.; Keller, A.; Nietsch, R.; Feng, Z.; Müller, S.; Kayvanpour, E.; Vogel, B.; et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur. Heart J. 2015, 36, 1123–1135a.
  42. Merlo, M.; Stolfo, D.; Anzini, M.; Negri, F.; Pinamonti, B.; Barbati, G.; Ramani, F.; Lenarda, A.D.; Sinagra, G. Persistent recovery of normal left ventricular function and dimension in idiopathic dilated cardiomyopathy during long-term follow-up: Does real healing exist? J. Am. Heart Assoc. 2015, 4, e001504.
  43. Zakrzewska-Koperska, J.; Franaszczyk, M.; Bilińska, Z.; Truszkowska, G.; Karczmarz, M.; Szumowski, Ł.; Zieliński, T.; Płoski, R.; Bilińska, M. Rapid and effective response of the R222Q SCN5A to quinidine treatment in a patient with Purkinje-related ventricular arrhythmia and familial dilated cardiomyopathy: A case report. BMC Med. Genet. 2018, 19, 94.
  44. Rubiś, P.; Wiśniowska-Śmialek, S.; Wypasek, E.; Biernacka-Fijalkowska, B.; Rudnicka-Sosin, L.; Dziewiecka, E.; Faltyn, P.; Khachatryan, L.; Karabinowska, A.; Kozanecki, A.; et al. Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathy. Inflamm. Res. 2016, 65, 941–949.
  45. Kimura, Y.; Okumura, T.; Morimoto, R.; Kazama, S.; Shibata, N.; Oishi, H.; Araki, T.; Mizutani, T.; Kuwayama, T.; Hiraiwa, H.; et al. A clinical score for predicting left ventricular reverse remodelling in patients with dilated cardiomyopathy. ESC Heart Fail. 2021, 8, 1359–1368.
  46. Cannatà, A.; De Angelis, G.; Boscutti, A.; Normand, C.; Artico, J.; Gentile, P.; Zecchin, M.; Heymans, S.; Merlo, M.; Sinagra, G. Arrhythmic risk stratification in non-ischaemic dilated cardiomyopathy beyond ejection fraction. Heart 2020, 106, 656–664.
  47. Neilan, T.G.; Coelho-Filho, O.R.; Danik, S.B.; Shah, R.V.; Dodson, J.A.; Verdini, D.J.; Tokuda, M.; Daly, C.A.; Tedrow, U.B.; Stevenson, W.G.; et al. CMR quantification of myocardial scar provides additive prognostic information in nonischemic cardiomyopathy. JACC Cardiovasc. Imaging 2013, 6, 944–954.
  48. Barison, A.; Aimo, A.; Ortalda, A.; Todiere, G.; Grigoratos, C.; Passino, C.; Camici, P.G.; Aquaro, G.D.; Emdin, M. Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy. Int. J. Cardiol. 2018, 250, 195–200.
  49. Merlo, M.; Masè, M.; Vitrella, G.; Belgrano, M.; Faganello, G.; Di Giusto, F.; Boscutti, A.; Gobbo, M.; Gigli, M.; Altinier, A.; et al. Usefulness of Addition of Magnetic Resonance Imaging to Echocardiographic Imaging to Predict Left Ventricular Reverse Remodeling in Patients With Nonischemic Cardiomyopathy. Am. J. Cardiol. 2018, 122, 490–497.
  50. Höke, U.; Khidir, M.J.; van der Geest, R.J.; Schalij, M.J.; Bax, J.J.; Delgado, V.; Ajmone Marsan, N. Relation of Myocardial Contrast-Enhanced T(1) Mapping by Cardiac Magnetic Resonance to Left Ventricular Reverse Remodeling After Cardiac Resynchronization Therapy in Patients With Nonischemic Cardiomyopathy. Am. J. Cardiol. 2017, 119, 1456–1462.
  51. Tobita, T.; Nomura, S.; Fujita, T.; Morita, H.; Asano, Y.; Onoue, K.; Ito, M.; Imai, Y.; Suzuki, A.; Ko, T.; et al. Genetic basis of cardiomyopathy and the genotypes involved in prognosis and left ventricular reverse remodeling. Sci. Rep. 2018, 8, 1998.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback